Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 19/20 | 0.57 |
| ▸ | MMP13 | P45452 | 17/20 | 0.57 |
| ▸ | MMP2 | P08253 | 13/20 | 0.57 |
| ▸ | MMP3 | P08254 | 11/20 | 0.57 |
| ▸ | MMP7 | P09237 | 10/20 | 0.57 |
| ▸ | MMP9 | P14780 | 8/20 | 0.57 |
| ▸ | MMP8 | P22894 | 6/20 | 0.57 |
| ▸ | MMP14 | P50281 | 2/20 | 0.54 |
| ▸ | ADAM17 | P78536 | 9/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7164719 | 1.00 | MMP1 (0.57) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7159157 | 0.97 | MMP1 (0.58) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7162951 | 0.90 | MMP1 (0.44) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7161396 | 0.89 | MMP1 (0.44) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7161390 | 0.89 | MMP1 (0.44) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7160213 | 0.86 | MMP1 (0.43) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7219734 | 0.84 | MMP1 (0.63) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7163437 | 0.83 | MMP1 (0.58) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7163665 | 0.83 | MMP1 (0.58) | MMP1MMP13MMP2MMP3MMP7 | |
| SCHEMBL7166258 | 0.82 | MMP1 (0.58) | MMP1MMP13MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6555535-B2 | Anticancer, antiarthritic, and antiinflammatory agents, and heart failure treatment | WARNER-LAMBERT COMPANY | 2003-04-29 | — | — | US | claimed |
| US-20020156071-A1 | Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors | O'BRIEN PATRICK MICHAEL (US) | 2002-10-24 | — | — | US | claimed |
| EP-1233018-A2 | Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-08-21 | — | — | EP | claimed |
| US-6555535-B2 | Anticancer, antiarthritic, and antiinflammatory agents, and heart failure treatment | WARNER-LAMBERT COMPANY | 2003-04-29 | — | — | US | disclosed |
| US-20020156071-A1 | Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors | O'BRIEN PATRICK MICHAEL (US) | 2002-10-24 | — | — | US | disclosed |
| EP-1233018-A2 | Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156071-A1 | Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors | MMP1, MMP9, MMP3 | MMP1 1/4885MMP13 9/4885MMP2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.